Reading your posts, it’s more apparent than ever that there are a heck of a lot of companies pursing VTA’s and related approaches to cancer treatment. Given the finite pool of patients and, more important, the limited pool of reimbursement dollars, it is mathematically impossible for all of these drug candidates to become big-selling drugs.
Does this make you a tad wary of the economic underpinning of investing in this sector?